LEXEO THERAPEUTICS INC (LXEO)
US52886X1072 - Common Stock
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer...
Lexeo Therapeutics Becomes Oversold (LXEO)
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...
Lexeo Therapeutics Becomes Oversold (LXEO)
Relative Strength Alert For Lexeo Therapeutics
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024...
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexeo Therapeutics (NASDAQ:LXEO) just reported results for the second quarter o...
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no...
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease.
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline ...
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering...
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors ...
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights...
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics to Participate in Upcoming Investor Conferences...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006...
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing ...
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into...
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S.
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing...
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments...